Professor Shy Arkin is Vice President, Chairman of the Authority for Research and Development at The Hebrew University of Jerusalem. The youngest person ever to be appointed to this position, he is a driving force for critical economic growth for the future and security of the State of Israel. Professor Arkin is a director of Yissum, the technology transfer company of The Hebrew University, which is responsible for marketing the inventions and know-how generated by the University's renowned researchers and students. More than 110 spin-off companies, including Mobileye, Briefcam, Keryx, Nasvax, and Novagali have had their start there. Yissum maintains strong relationships with the business community in Israel and abroad to advance the technologies and opportunities coming out of The Hebrew University.Professor Arkin earned his Bachelor’s degrees at Hebrew University’s Robert H. Smith Faculty of Agriculture, Food and Environment and at the Faculty of Life Sciences at Tel Aviv University. He received his Ph.D. in cell biology from Yale University. After serving as a lecturer in the Department of Biochemistry at Cambridge University in England, Professor Arkin joined The Hebrew University faculty (2001). The renowned scholar and scientist is a former chair of the University’s Alexander Silberman Institute of Life Sciences. Professor Arkin’s work is widely published in international journals. He is the recipient of numerous awards and research grants and is a frequent guest speaker at global conferences.Professor Arkin’s research utilizes computational science and bioinformatics to investigate the structural biology of membrane proteins. His work, which is based on novel experimental techniques, focuses on revealing the structure of membrane proteins. Professor Arkin's techniques have succeeded in shedding new light on the cell penetration mechanisms of the flu virus and SARS, and in the special folding of proteins responsible for Huntington's disease.
If you are interested in learning more about TIGER 21, please complete the contact form and you will receive a copy of our most recent Asset Allocation Report.